Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

COR Therapeutics' cardiovascular drug candidate enters phase I trials

Feb. 5, 1997

DuPont Merck reports new fibrinogen antagonists

Jan. 31, 1997

New anticoagulant drug candidates from Berlex

Jan. 31, 1997

Serine protease inhibitors reported by Akzo Nobel

Jan. 31, 1997

Dutch investigators find method of improving t-PA therapy

Jan. 30, 1997

Pivotal Integrilin study fully enrolled

Jan. 29, 1997

Thrombin inhibitors from BioChem Pharma

Jan. 28, 1997

Searle describes new platelet aggregation inhibitors

Jan. 28, 1997

Antithrombotics described by Terumo

Jan. 27, 1997

Sumitomo claims antiplatelet agents

Jan. 27, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...